SITC
WuXi AppTec offers an end-to-end platform of immuno-oncology services to support drug discovery teams. Stop by booth #230 to learn about our unrivalled portfolio of PDX, CDX, and syngeneic tumor models. Our capabilities also include PBMC humanized mouse models, tissue-based biomarker analysis for checkpoint inhibitors, bispecific antibodies, and CAR-T/TCR-T cell therapy services.
| Posters |
| Abstract ID: 237522 Engineered oncolytic viruses expressing immunomodulatory genes enhances in vitro anti-tumor cellular immune responses Abstract ID: 214043 PD-1 blockade protein in 4th generation armored CAR-T cells enhances cytotoxicity effect with in vitro re-challenge system |
| Participants |
| Dr. Declan Ryan, Vice President of Business Development, WuXi AppTec Yu Chen, Director of Business Development, WuXi AppTec Mahnaz Arjomand, Executive Director of Business Development, WuXi AppTec Dr. Luping Lin, Director, Discovery Biology, WuXi AppTec Xiangnan Qiang, Associate Director, WuXi AppTec |